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Abstract: The PtII linker [ethylenediamineplatinum(II)]2+,
coined Lx, has emerged as a novel non-conventional approach
to antibody–drug conjugates (ADCs) and has shown its
potential in preclinical in vitro and in vivo benchmark studies.
A crucial improvement of the Lx conjugation reaction from
initially < 15% to ca. 75–90 % conjugation efficiency is
described, resulting from a systematic screening of all relevant
reaction parameters. NaI, a strikingly simple inorganic salt
additive, greatly improves the conjugation efficiency as well as
the conjugation selectivity simply by exchanging the leaving
chloride ligand on Cl-Lx-drug complexes (which are direct
precursors for Lx-ADCs) for iodide, thus generating I-Lx-drug
complexes as more reactive species. Using this iodide effect, we
developed a general and highly practical conjugation proce-
dure that is scalable: our lead Lx-ADC was produced on a 5 g
scale with an outstanding conjugation efficiency of 89 %.
Introduction
Antibody–drug conjugates (ADCs) are Trojan horses of
medicinal chemistry: they are a targeted approach to treat
cancer allowing selective delivery of effector molecules
(payloads), such as cytotoxic or immune-modulating thera-
peutics, to malignant cells, thereby sparing healthy cells. The
advancements in the ADC field and the role of organic
chemistry in ADC development were recently highlighted in
a review.[1] Currently, nine ADCs have been approved by the
Food and Drug Administration (FDA): Adcetris, Kadcyla,
Mylotarg, Besponsa, Polivy, Padcev, Enhertu, Trodelvy, and
Blenrep (the last two approved in 2020), with > 80 ADCs
currently in active clinical evaluation.[2a] ADCs are utmost
complex to develop[2b–d] and comprise three components:
a disease-selective monoclonal antibody (mAb), a small-
molecule therapeutic payload (drug), and a linker which
connects the two parts. Linkers are the most modifiable part
of an ADC and often form a critical factor in the efficiency
and costs of the production process, as well as in the
therapeutic efficacy and tolerability of an ADC.[3a–c]
To attach a drug-linker moiety to a mAb, a bioconjugation
procedure is applied. Generally, the conjugation step is key
for every ADC technology, since it not only dictates the
nature and characteristics of the bioconjugate, but also the
efficiency of the conjugation, that is, the percentage of the
offered drug-linker moiety that is effectively coupled to the
antibody. An efficient conjugation reaction will strongly
contribute to the ultimate success of any ADC.
Typical conjugation approaches are the stochastic (ran-
dom) conjugation to lysine (Lys) residues and the conjugation
to reduced cysteine (Cys) residues in the hinge region of the
mAb, along with a variety of more recently developed
techniques.[4] The site-specific conjugation[5] was clearly
a major trend during the last years; nevertheless, a recent
publication showed that heterogeneous stochastic conjuga-
tion can be beneficial over homogeneous site-specific con-
jugation.[5a] However, even modern site-specific conjugation
procedures using, for example, genetically engineered amino
acids or enzymatic approaches[6] mainly focus on the efficacy
of the resulting ADCs or improvement of their pharmacoki-
netics/pharmacodynamics. Surprisingly, little attention is paid
to the overall conjugation efficiency and manufacturability of
the developed procedures. Therefore, desired conversions are
typically achieved by addition of a large excess of a drug-
linker reagent, just to ensure a complete conjugation. Even
a recent paper describing manufacturing of 1.7 g of an ADC
under good manufacturing practice (GMP) using a site-
specific technology still uses as much as 10 equiv of the
payload-spacer moiety to obtain an average drug-to-antibody
ratio (DAR) of 1.6, which corresponds to a 16% conjugation
efficiency only.[7] Thus, currently there are clear unmet needs
in the development and manufacturing of ADCs.
[*] Dr. E. Merkul, J. A. Muns, Dr. N. J. Sijbrandi, Prof. Dr. H.-J. Houthoff,
Dr. B. Nijmeijer, G. van Rheenen
Chemistry Department, LinXis BV
De Boelelaan 1085c, Amsterdam, 1081 HV (The Netherlands)
E-mail: merkul@linxispharmaceuticals.com
Prof. Dr. J. Reedijk
Leiden Institute of Chemistry, Leiden University
PO Box 9502, 2300 RA Leiden (The Netherlands)
Prof. Dr. G. A. M. S. van Dongen
Department of Radiology and Nuclear Medicine, Amsterdam UMC,
location VU medical center
Amsterdam (The Netherlands)
Supporting information and the ORCID identification number(s) for
the author(s) of this article can be found under:
https://doi.org/10.1002/anie.202011593.
 2020 LinXis BV. Angewandte Chemie International Edition
published by Wiley-VCH GmbH. This is an open access article under
the terms of the Creative Commons Attribution Non-Commercial
NoDerivs License, which permits use and distribution in any
medium, provided the original work is properly cited, the use is non-
commercial and no modifications or adaptations are made.
Angewandte
ChemieResearch Articles
How to cite: Angew. Chem. Int. Ed. 2021, 60, 3008–3015
International Edition: doi.org/10.1002/anie.202011593
German Edition: doi.org/10.1002/ange.202011593
3008  2020 LinXis BV. Angewandte Chemie International Edition published by Wiley-VCH GmbH Angew. Chem. Int. Ed. 2021, 60, 3008 – 3015
Some years ago, we introduced a novel approach to an
improved ADC linker design by developing a cationic metal-
organic PtII-based linker, [ethylenediamineplatinum(II)]2+,
which we coined Lx.[8a–d] The Lx conjugation is a stochastic
conjugation technology, which (uniquely among ADC con-
jugation methods) addresses histidine (His) residues of native
unmodified antibodies for a stable drug-linker attachment.
This straightforward ADC linker technology might be
a valuable addition to the field of next-generation ADCs
based on its in vitro and in vivo performance, as summarized
in our recent technology review.[8c]
The Lx-technology is based on the remarkable stability of
PtII–N coordination compounds[9] and a high affinity of the
PtII center towards N- and S-donor biomolecules,[10] including
proteins.[11]
The concept consists of two key steps: “complexation”
and conjugation (Scheme 1 depicts details of the initial
conjugation conditions and Scheme 4, left, shows the general
Lx-approach, as it was initially described[8a]).
In the first step (complexation), the commercially avail-
able precursor complex LxCl2 bearing two cis-oriented
chlorido leaving ligands can be coordinated to payloads/
drugs bearing a suitable coordination group (CG). Typically,
CG is an N-heterocycle, such as piperidine, which provides
a stable bond to Lx ; all constructs used in this work utilize
piperidine as a CG. As a result of the complexation step,
stable intermediate products, which we coined semi-final
complexes, are obtained comprising the payload and one
chlorido leaving ligand. These semi-final products contain
a positively charged PtII center, which increases the water
solubility of drug-linker moieties compared to analogous non-
Lx containing constructs. Recently, we described an improve-
ment of the complexation reaction and the development of
a highly efficient, versatile, and green approach to iodido
semi-final complexes,[12] which unexpectedly turned out to be
beneficial for the Lx conjugation, as will be outlined below.
Both chlorido and iodido semi-final compounds can be stored
at low temperatures for > 1 year without decomposition.
In the second step (conjugation), the obtained semi-final
complexes are conjugated to the imidazole moiety of His
residues of unmodified mAbs, taking advantage of a high
intrinsic preference of the PtII center to such N-donor
ligands.[13] In principle, besides His, PtII is able to coordinate
to reduced Cys (which are not present in native mAbs) and to
methionine (Met) residues of proteins.[10b,14, 28] Therefore, we
introduced a thiourea (TU) quenching step[15] to ensure
stability and reproducibility of the obtained Lx conjugates.
Owing to a high affinity of TU (which was even suggested as
a rescue agent in cisplatin therapy)[10b] to PtII, it removes the
kinetically formed but thermodynamically labile Met-bound
Lx-payload complexes, leaving only the thermodynamically
more stable and kinetically inert His-bound Lx-payload
complexes intact.[16]
The bottleneck of our initial approach (Scheme 1; Sup-
porting Information, Section 2) was the low conjugation
efficiency of ca. 13%. To obtain an average DAR of about
2.5, which is the desired DAR for our proposed clinical lead
candidate ADC trastuzumab-Lx-AF,[8a] as much as 20 equiv
of the linker-payload semi-final complex Cl-Lx-AF were
required, meaning that ca. 87% of this precious compound
was wasted. Such a poor conjugation efficiency is clearly
unacceptable for any clinical application.
We therefore set the goal to develop a general and
efficient conjugation procedure which could be easily and
reproducibly applied on a large scale.
Results and Discussion
Herein we describe a comprehensive optimization study
of the Lx conjugation procedure and important insights and
findings that were made. The validation of the newly
developed method, the multigram scale synthesis of a lead
Lx-ADC, and the advanced Lx-technology are described
below. The full description of all experiments is presented in
the Supporting Information, Sections 3–7.
To substantially improve the Lx conjugation procedure,
we performed a broad and detailed optimization of all
relevant reaction parameters. For this optimization work,
we choose a Desferal (DFO) based model semi-final complex
1a (Figure 1) and investigated its conjugation reaction to
trastuzumab (Herceptin).
The model compound 1a contains a DFO–FeIII complex,
coordinated to Lx via a piperidine coordination group, the
same CG as used in our clinical lead candidate.[8a] It has
several important advantages that make it a valuable model
compound for the intended optimization study (Supporting
Information, Section 3.1). For the method of determination of
the conjugation efficiency used for this optimization study, see
the Supporting Information, Section 3.2 and Figure S1.
First, a broad screening of different buffers in the pH
range of 2.7–10.4 (Supporting Information, Section 3.3)
revealed the optimal buffer, 20 mM 2-[4-(2-hydroxyethyl)pi-
Scheme 1. The initial conditions of the Lx conjugation. The drug–Lx
part of the ADC is taken into square brackets, showing its correspond-
ing pH independent charge on PtII.
Figure 1. Structures of the Hal-Lx-DFO-FeIII (Hal-Lx) semi-final com-
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perazin-1-yl] ethanesulfonic acid (HEPES) of pH 8.1, which
provided a minor increase in the conjugation efficiency (from
ca. 15 % to ca. 21%; Supporting Information, Figure S3)
compared to the previously used tricine buffer of pH 8.5.[8a]
In the next step, we investigated the influence of inorganic
salts on the Lx conjugation efficiency, since they can interact
both with a protein and with a semi-final complex 1.
Assuming that anions would have a stronger effect than
cations, we performed a broad screening of sodium salts
(Figure 2; Supporting Information, Section 3.5.1).
Confirming an early observation,[16] it was found that
NaClO4 and Na2SO4 showed a minor increase in the
conjugation efficiency, likely explainable by their interaction
with the mAb.[17] However, most spectacular results were
observed when NaI and (to a lesser extent) NaBr were added.
Addition of NaI resulted in a conjugation efficiency of ca.
38% (ca. 36 % when NaBr was used), which was significantly
higher compared to the conjugation without addition of a salt
(ca. 21%) or using the negative control salt NaIO3 (ca. 22%)
that also contains iodine, but cannot release the iodide anion.
In this case, the interaction of the salt with the protein is of
minor importance and this outcome can be rationalized by an
interaction of the salt (NaI or NaBr) with the PtII complex 1a.
Most likely, the enhancement happened through an inter-
mediate formation of the bromido and iodido semi-final
complexes 1b and 1 c (Figure 1), respectively, from the parent
chlorido semi-final complex 1a, which was later shown to be
a rapid process (Supporting Information, Section 3.7). Inter-
estingly, a diiodido PtII carbohydrate complex was described
as less reactive towards a model N-nucleophile compared to
its dichlorido counterpart.[18] Later, slower binding of the
diiodido analog of cisplatin, cis-PtI2(NH3)2, to DNA was
confirmed and was explained by its slower hydrolysis.[19] Thus,
previous reports suggested that an I–Lx complex should be
less reactive towards N-nucleophiles than a Cl–Lx complex,
but we observed exactly the opposite. Therefore, our current
finding of a faster reaction of I–PtII complexes with biomol-
ecules compared to their chlorido counterparts is non-trivial
and counterintuitive and remains unprecedented.
Generally, after an initial finding that cis-PtI2(NH3)2 was
less anticancer-active compared with cisplatin,[20] the I–PtII
complexes, which were since then stigmatized to be inert and
unreactive,[21] remained in the sleeping beauty slumber for
successive four decades, being totally neglected and over-
looked by medicinal chemists. Nevertheless, they remained to
be extensively utilized as very useful synthetic precursors (by
Ag+ mediated ligand exchange) for numerous cisplatin
analogues, for example, in the well-known Dharas method
for the synthesis of cisplatin[22a] and its modified procedur-
es.[22b,c] However, I-PtII complexes are now experiencing their
renaissance[23] following the recognition of their intriguing
properties, so that we will probably see a lot of interesting
novel anti-cancer compounds of this class in the near future.
After successful screening of anions, a large variety of
iodide and bromide salts has been screened (Supporting
Information, Section 3.5.2). It was found that the nature of the
cation did not have a profound effect on the Lx conjugation
efficiency (Supporting Information, Figure S8). Therefore, we
decided to implement NaI routinely as a simple inorganic salt
additive for the Lx conjugation reactions, at a concentration
of 10 mM (Supporting Information, Figure S7), which corre-
sponds to an I :PtII ratio of about 6:1.
Besides inorganic salts, also other additives that may have
effects on the Lx conjugation reaction, such as amino acids,
were tested (Supporting Information, Section 3.6). Namely, if
these compounds are able to coordinate to PtII, they can
compete with coordination sites of the antibody for binding to
Lx. This can have an effect on the Lx conjugation efficiency
depending on the reactivity of the intermediate PtII additive
thus formed. For example, L-His is present in the clinical
formulation buffer of Herceptin (trastuzumab) and can
therefore affect the Lx conjugation (see below).
Previous reports suggest that formation of stable PtII-His
complexes can be more efficient owing to transplatination
after formation of kinetically favored but thermodynamically
less stable PtII–Met complexes.[10b, 24] Based on this knowledge,
our working hypothesis for the Lx conjugation was that
initially the coordination of an Lx semi-final complex 1 to
Met residues of an antibody takes place, followed by a shift of
a payload-Lx moiety to His residues. We assumed therefore
that the addition of Met derivatives or other soft nucleophiles
could increase the Lx conjugation efficiency.[25] Moreover,
these experiments would provide further insight into the
binding sites of Lx on antibodies (a particular attention was
paid to His, Met, Cys, Lys, and arginine (Arg) as potential
binding spots for Lx) and into the influence of NaI on the
affinity of Lx to those amino acids.
It was found that none of the tested additives significantly
increased the Lx conjugation efficiency and that additives
capable of coordination to Lx diminished the conjugation
efficiency (Supporting Information, Figure S9), thus disprov-
ing the hypothesis that Met-adducts are productive inter-
mediates on the way towards the His-adducts.[26] Met and Cys
almost completely inhibited the Lx conjugation, His (and
imidazole as its heterocyclic core) considerably diminished it,
whereas Lys and Arg were found much less inhibiting
(Figure 3). It confirmed our previous conclusion and litera-
ture knowledge that Cys (in case the mAb is reduced before
conjugation), Met, and His are preferable Lx binding sites.
Most interestingly, it appeared that Met inhibits the Lx
Figure 2. Conjugation efficiency in the presence of various sodium salt
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conjugation stronger in the absence of NaI, whereas for His
the opposite is the case (Figure 3). This unexpected finding
suggests that addition of NaI to the conjugation mixture
improves the selectivity/affinity of the Lx conjugation to-
wards the desired His-binding over the undesired Met-
binding (see also below).
Having achieved a conjugation efficiency of about 38 %,
at this stage we decided to fine-tune the Lx stoichiometry and
lowered the excess of Cl-Lx (1a) to 5 equiv instead of
20 equiv (Supporting Information, Section 3.7). This led to an
increase in the conjugation efficiency to about 48 %, corre-
sponding to the desired average DAR of about 2.5 (Support-
ing Information, Figure S11). Thus, the optimization achieved
to this point allowed use of less payload-Lx to obtain the
desired average DAR, resulting in an increased conjugation
efficiency due to a more efficient conjugation to accessible
His residues.
In a next stage, we investigated the effect of the TU
quenching/washing step (Supporting Information, Sec-
tion 3.10) that was introduced to ensure stability of Lx
conjugates by stripping off weakly bound Lx-complexes (see
above). While having a profound effect on the conjugation
efficiency in the absence of NaI (indicating profound
formation of weakly Met-bound Lx-payload complexes) for
conjugation times < 24 h, the effect of the TU quenching step
became hardly detectable when NaI had been present during
the conjugation (Supporting Information, Figure S15).
This observation confirms that addition of NaI does not
only make the Lx-complex more reactive towards proteins
(resulting in higher efficiency of the conjugation), but it also
makes it more selective for the desired stable binding to His at
the cost of the undesired weak binding to Met, in line with
results above. This improved selectivity could be explained by
a more rapid equilibrium between starting I-Lx complexes
and labile dead-end Met-Lx complexes in the presence of an
excess of NaI.
Based on conclusions from earlier experiments,[16] no
removal of L-His, which can compete with His binding sites of
trastuzumab for conjugation, from the Lx conjugation
mixtures was undertaken yet. However, after it was found
that L-His was indeed detrimental for the Lx conjugation
reaction (ca. 80% decrease in the presence of NaI; Figure 3),
a buffer exchange step of the antibody before the Lx
conjugation had to be introduced (Supporting Information,
Section 3.11). Consequently, removal of L-His from the
native trastuzumab formulation buffer greatly improved the
conjugation efficiency (from ca. 45 % to ca. 80%) after 24 h
conjugation time (Supporting Information, Figure S17).
To demonstrate the generality of the Lx conjugation, it
was applied to five representative mAbs (Supporting Infor-
mation, Section 3.12). We found similar conjugation efficien-
cies in the range of 74–78% after 24 h conjugation time,
indicating that our newly developed conjugation procedure is
not restricted to trastuzumab but can be applied to a broad
range of mAbs (Supporting Information, Figure S19).
Finally, the effect of the halido leaving ligand on the
conjugation efficiency was investigated in detail (Supporting
Information, Section 3.13). For that purpose, we compared all
three halido semi-final complexes 1 a–c (Figure 1) that were
synthesized and isolated for this experiment (Supporting
Information, Scheme S15). As first, their hydrolytic stability
was assessed. We found that stabilizing concentrations of the
corresponding halide salts were necessary to preserve the
semi-final complexes 1a–c from hydrolysis (that is, formation
of an unreactive HO-Lx species), when they were incubated
under Lx conjugation conditions, but without the mAb.
Noteworthy, the concentration of the corresponding stabiliz-
ing salt reflected the hydrolytic stability of the semi-final
complexes. For Cl-Lx (1c), a high concentration of 200 mM
NaCl was required to keep > 90% of the semi-final complex
intact for 4 h under the conjugation conditions (Supporting
Information, Figure S25), whereas for Br-Lx (1 b) and I-Lx
(1c), concentrations of 50 mM NaBr (Supporting Informa-
tion, Figure S26) and 10 mM NaI (Supporting Information,
Figure S27), respectively, were found to be sufficient. There-
fore, the hydrolytic stability of semi-final complexes follows
the row: 1 c> 1b> 1a, which is fully in line with the described
higher hydrolytic stability of for example, cis-PtI2(NH3)2 vs.
cisplatin.[19] Therefore, to explore the net effect of the halido
leaving ligand without interference of hydrolysis, conjuga-
tions of complexes 1 a–c were performed in the presence of
the corresponding halide salts, in concentrations sufficient to
preserve the aforementioned semi-final complexes from
hydrolysis (Figure 4 A). We found that the conjugation
efficiency was highest for I-Lx (1c)/10 mM NaI (90 %),
followed by Br-Lx (1b)/50 mM NaBr (74 %), and was lowest
for Cl-Lx (1a)/200 mM NaCl (34 %). An attempt to prepare
the F-Lx complex 1d (Figure 1) failed: it turned out to be too
unstable towards hydrolysis to be isolated.
Another important finding is that the halido leaving
ligand of the starting Hal-Lx complexes 1 can be freely chosen
from iodido, bromido, and chlorido ligands: in case an
external iodide source will be added into the Lx conjugation
mixture, all semi-final complexes 1 will generate the desired
Lx-ADC at the same rate and with the same efficiency (ca.
80% after 24 h; Figure 4B) because of a rapid exchange of
a halido to the iodido ligand, thus resulting in a common semi-
final compound 1c. Hence, regardless of which semi-final
complex is used (be it Cl–Lx-drug, Br–Lx-drug, or I–Lx-drug
complex) the addition of a certain concentration of an iodide
salt to the aqueous conjugation mixture ensures an outstand-
Figure 3. Normalized conjugation efficiency in the presence of selected
additives (30 mM), in the absence or presence of NaI (10 mM).
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ing efficiency of the Lx conjugation reaction. The iodide
effect was already noticeable at an I :PtII ratio of about 0.6:1
(thus, at catalytic concentrations; Supporting Information,
Figure S7), however, a ratio of about 30:1 is standardly used
in current optimized procedures.
As yet we do not fully understand why the iodido species
perform so much better in the Lx conjugation reaction
compared with the chlorido species and considerably better
than the bromido species, both in terms of conjugation
efficiency and conjugation selectivity. A main reason might be
that I–PtII complexes are thermodynamically more stable
(which, for example, can be seen in their higher hydrolytic
stability described above), but at the same time they are
kinetically more labile compared with Cl–PtII complexes
(Br–PtII complexes being in between[27]), allowing a very
efficient step towards conjugation. Interestingly, an X-ray
crystallographic structural analysis of an adduct of cis-PtI2-
(NH3)2 with lysozyme revealed that, although the complex
also preferred a His residue for binding, it was not the iodide
but rather the ammonia ligand that was released.[28a] Recently,
the same authors described a complicated binding behavior of
cis-PtI2(NH3)2 to cytochrome c, indicating that loss of both
iodide and ammonia ligands is possible.[28b] Having a stabiliz-
ing bidentate ligand ethylenediamine as a structural part of
Lx, we never observed its release, despite the notoriously
strong trans effect of iodide.
The Lx conjugation has been optimized successfully, as
presented in detail above. However, the biological properties
of the conjugates obtained by the newly developed method
required validation. In particular, in case that the optimized
method would deliver inferior conjugates the whole optimi-
zation endeavor would become useless.
Therefore, first the Cl-Lx-DFO-FeIII model semi-final
complex 1a was used to compare the optimized and the initial
methods and to verify that the properties of the thus obtained
Lx conjugates 2a and 2b remained unaltered (Supporting
Information, Section 4). FeIII can be easily replaced by the
positron emitting isotope 89ZrIV, a widely used nuclide in the
positron emission tomography (PET) imaging of mAbs.[8b,29]
Thus, by means of 89Zr labeling, the comparison of the human
epidermal growth factor receptor 2 (HER2) binding proper-
ties (Supporting Information, Figure S30), serum stability
(Supporting Information, Figure S31), biodistribution (Fig-
ure 5A), and pharmacokinetics (Figure 5B) revealed that the
properties of the two conjugates 2a/2b were identical, while
the Lx conjugation efficiency increased from ca. 13 % to
about 76 % (Scheme 2).
Next, we applied the Lx conjugation procedure using
iodide (optimized method) to the semi-final complex Cl-Lx-
Figure 4. Conjugation efficiency obtained in the presence of corre-
sponding sodium halide salts for stabilization of the Hal-Lx complexes
1a–c (A) and in the presence of NaI (10 mM) for the Hal-Lx complexes
1a–c (B).
Figure 5. Biodistribution 72 h after injection (A) and blood kinetics (B)
of 4 mgkg1 dose of radiolabeled Lx conjugates 89Zr-2a (black bars
and black line; initial method) and 89Zr-2 b (gray bars and gray line;
optimized method) in NCI-N87 xenograft bearing mice (N = 6/group),
both assessed by 89Zr counting. The error bars represent the standard
deviation (SD).
Scheme 2. Synthesis of the Lx conjugates trastuzumab-Lx-DFO-FeIII
(2a and 2b) from the chlorido semi-final complex Cl-Lx-DFO-FeIII (1a),
comparing the initial and the optimized Lx conjugation methods.
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AF (1 f) that bears the supertoxic payload auristatin F,
yielding AF-based Lx conjugate 3 b with ca. 85 % efficiency
(Scheme 3; Supporting Information, Section 5). Its properties
were compared to the properties of the conjugate 3 a obtained
via the initial Lx conjugation method with ca. 13 % efficiency.
It was confirmed that the DAR as well as the payload
distribution on the antibody were similar for both Lx
conjugates (Supporting Information, Section 5.2). These re-
sults also confirmed our hypothesis that the optimized Lx
conjugation method provides an impressive improvement of
the conjugation efficiency without changing/affecting the
properties of the final Lx-ADC product (thus, 3a = 3 b).
Expectedly, the cell titer blue (CTB) based cytotoxicity
bioassay of conjugates 3a and 3b provided very similar
picomolar half-maximal inhibitory concentration (IC50) val-
ues for both conjugates in HER2-positive cell lines NCI-N87,
SK-OV-3, and JIMT-1 (results for JIMT-1 are shown in
Figure 6; for all cell lines in the Supporting Information,
Figure S34).
Thus, we successfully confirmed the validity of the
optimized method for two payloads: DFO and AF.
Additionally, stability of the lead product Lx-ADC was
confirmed by a formulation stability study of a batch 3bstab
(Supporting Information, Section 6).
To test the scalability of the newly developed Lx
conjugation method, we performed a multigram (5.1 g) scale
synthesis of our lead Lx-ADC 3c (Supporting Information,
Section 7) from a trastuzumab biosimilar and 2.5 equiv of I-
Lx-AF (1g), which was produced previously on a 16 g scale
using the recently published procedure for the synthesis of
iodido semi-final complexes.[12]
After the conjugation using the optimized method, the
obtained product 3c was quality controlled against five
products of milligram scale conjugation reactions (3cref) that
were run in parallel to the multigram conjugation using the
same conjugation mixture; the results of the quality control of
the obtained multigram scale batch are summarized in the
Supporting Information, Table S29.
The obtained multigram scale conjugate 3c showed
properties, such as protein content (Supporting Information,
Table S30), monomeric purity (Supporting Information, Fig-
ure S36 and Table S31), average DAR (Supporting Informa-
tion, Figure S38 and Table S32), and potency (Supporting
Information, Figure S39 and Table S33), very similar to the
milligram scale reference conjugates 3cref (thus, 3c = 3cref).
This confirmed that the upscaling went successfully without
any complications. With the determined DAR of about 2.2
(by size-exclusion chromatography-mass spectrometry (SEC-
MS)), which is in the anticipated range of 2.1–2.8, the
conjugation efficiency of about 89 % was found to be high
and fully met the expectations.
The results obtained in this work convincingly show that
the Lx-linker technology has become a mature bioconju-
gation method and the Lx-platform advanced from a promis-
ing proof of concept (Scheme 4, left) to a straightforward,
robust, and general approach to ADCs (Scheme 4, right).
Both key steps of the greatly improved Lx-technology,
complexation and conjugation, are aligned and work highly
synergistically. Namely, the recently developed direct Ag-free
complexation[12] method of preparing the iodido semi-final
complexes delivers perfect precursors for the subsequent Lx
conjugation, as was discovered in the course of the optimi-
zation work described above. They are conveniently obtained
from a simple PtII precursor LxI2
[12, 30] and subsequently they
can be directly used in the herein developed iodide-promot-
ed/-catalyzed Lx conjugation procedure, having already the
optimal leaving ligand (iodide instead of chloride) installed.
Logically enough, the iodido semi-final complexes are
currently used as first-choice next-generation precursors for
the Lx conjugations.
Scheme 3. Synthesis of the Lx conjugates trastuzumab-Lx-AF (3a and
3b) from the chlorido semi-final complex Cl-Lx-AF (1 f), comparing the
initial and the optimized Lx conjugation methods.
Figure 6. The IC50 values of the Lx conjugates 3a and 3b in JIMT-1,
determined by a CTB assay.
Scheme 4. The initial Lx conjugation approach to ADCs with its two
crucial steps: complexation and conjugation (left) and the advanced Lx
technology, with both key steps greatly improved by use of iodide as
a ligand and as a salt additive (right).
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However, the Lx conjugation does not depend on the
nature of the halido leaving ligand of the semi-final complex
(see above): it can be produced as an iodido (currently our
routine and preferred synthesis route),[12] bromido or chlorido
complex depending on the particular synthetic need. This
convincingly demonstrates that the Lx-technology in its
current advanced state is highly modular and versatile,
offering (based on its technical aspects and favorable proper-
ties of the obtained ADCs)[8a,c] a valuable addition to the
repertoire of the currently existing bioconjugation ap-
proaches.
Conclusion
The exhaustive optimization described above has resulted
in a successful and rather surprising finding[31] that the
addition of iodide salts to the conjugation mixture greatly
improves the efficiency of the Lx conjugations.
The key mechanistic step of the discovered iodide effect is
a rapid halide exchange of the initially used chlorido semi-
final complexes,[8a] resulting in the formation of the corre-
sponding iodido semi-final complexes, which are hydrolyti-
cally more stable but at the same time more reactive and more
selective for His.
The current Lx conjugation technology making use of the
discovered iodide effect has matured to become a general,
robust, and preparatively simple approach to ADCs. The
demonstrated conjugation efficiency of 89 % during the
synthesis of our lead Lx-ADC on a multigram scale was
remarkably high. The method allows a straightforward cou-
pling of various payloads to native mAbs without any
chemical pre-modification or genetical engineering of the
antibodies. The new Lx-technology utilizes NaI, a harmless
salt that is used industrially as a nutritional supplement to
treat and prevent iodine deficiency, as a simple additive.
Further studies of new opportunities provided by the
discovered iodide effect are currently ongoing. Future work
will also focus on the GMP production of our lead Lx-ADCs,
toxicological studies, and first-in-human trials.
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